Type 1 Diabetes

Type 1 diabetes results from autoimmune beta-cell destruction and near-absolute insulin deficiency; insulinopenia predisposes to catabolism, hypertriglyceridemia, and diabetic ketoacidosis (DKA). ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 In adults, autoimmune diabetes is commonly misclassified as type 2 diabetes, delaying insulin and increasing DKA risk. Islet autoantibodies, particularly GAD antibodies with other islet autoantibodies, and C-peptide interpreted with concurrent glucose help resolve diagnostic uncertainty. ScienceDirectScienceDirectAdult-onset type 1 diabetes: early detection, differential diagnosis, and emerging disease-modifying therapies

At presentation with symptomatic hyperglycemia, weight loss, ketosis, or suspected insulin deficiency, assess plasma glucose, electrolytes, bicarbonate, pH, and beta-hydroxybutyrate promptly. DKA requires diabetes or glucose at least 200 mg/dL, beta-hydroxybutyrate at least 3.0 mmol/L or urine ketones at least 2+, and pH below 7.3 and/or bicarbonate below 18 mmol/L. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ... A prior diabetes history can satisfy the diabetes criterion in euglycemic DKA. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ...

ADA guidance recommends either continuous subcutaneous insulin infusion or multiple daily injections of basal plus prandial insulin for most adults with type 1 diabetes. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 Insulin analogs or inhaled prandial insulin are preferred over injectable human insulin when feasible because they reduce hypoglycemia risk. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 A basal-bolus regimen includes basal insulin for fasting and between-meal control plus rapid- or ultra-rapid-acting prandial insulin for meals and correction. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025

For metabolically stable adults, total daily insulin is often initiated around 0.5 units/kg/day, with approximately 30%-50% as basal insulin and the remainder as prandial insulin; requirements vary with residual endogenous insulin, age, puberty, illness, menses, pregnancy, diet, and activity. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 The source supports this as a typical starting framework, not a fixed dose algorithm. Reassess insulin-taking behavior, access, technique, and regimen every 3-6 months. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025

Teach carbohydrate-based meal dosing, correction dosing based on current glucose and trends, adjustment for anticipated activity, and sick-day management. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 Fat and protein can affect postprandial glycemia and may require individualized adjustment, especially with pump therapy. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 Inspect injection and infusion sites routinely; lipohypertrophy causes erratic absorption, glycemic variability, and unexplained hypoglycemia. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025

Assess glycemia with A1C and/or CGM metrics. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ... For people using CGM, review at least 14 days with active data at least 70% of the time for pattern management. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ... In most nonpregnant adults, target time in range of 70-180 mg/dL above 70%, time above 180 mg/dL below 25%, time above 250 mg/dL below 5%, time below 70 mg/dL below 4%, and time below 54 mg/dL below 1%. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ...

For many nonpregnant adults, an A1C goal below 7% is appropriate, with preprandial glucose 80-130 mg/dL and peak postprandial glucose below 180 mg/dL measured 1-2 hours after beginning a meal. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ... Goals must be relaxed when treatment burden or hypoglycemia risk exceeds expected benefit. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ... A1C is unreliable with altered erythrocyte turnover, including anemia, recent transfusion, erythropoiesis-stimulating therapy, end-stage kidney disease, and pregnancy; use CGM, blood glucose, fructosamine, or glycated albumin as appropriate. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ...

Early CGM improves glycemic outcomes and quality of life and reduces hypoglycemia in adults with type 1 diabetes. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 ADA recommends offering automated insulin delivery to all adults with type 1 diabetes; selection should account for ability to use the system safely, caregiver support, preferences, cost, and access. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025

Review hypoglycemia at every visit in all patients at risk and screen at least annually for impaired awareness. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ... Level 1 hypoglycemia is glucose below 70 mg/dL and at least 54 mg/dL; level 2 is below 54 mg/dL; level 3 is altered mental or physical status requiring assistance, regardless of measured glucose. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ... Level 2 or 3 events require prompt treatment-plan reassessment, including insulin deintensification or modification when appropriate. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ...

Prescribe glucagon for all people taking insulin or at high risk for hypoglycemia, and train family, caregivers, school staff, or others likely to assist. Ready-to-use formulations are preferred over products requiring reconstitution. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ... For a conscious patient with glucose below 70 mg/dL, administer fast-acting glucose-containing carbohydrate, recheck after 15 minutes, and repeat treatment if hypoglycemia persists. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ...

DKA prevention requires explicit sick-day rules. Patients on intensive insulin therapy should not stop basal insulin when not eating. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ... In those at risk, advise blood or urine ketone testing during illness, missed insulin, symptoms of DKA, or glucose above 200 mg/dL. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ... Patients who cannot tolerate oral hydration, do not improve with insulin, have altered mental status, or have worsening illness require immediate medical evaluation. ccjmccjm6. Glycemic Goals and Hypoglycemia: Standards of Care in ...

Stage 2 type 1 diabetes is presymptomatic autoimmune diabetes with dysglycemia. Teplizumab is the only FDA-approved disease-modifying therapy to delay progression from stage 2 to clinical stage 3 disease; FDA approval now includes children aged 1 year and older. BMJBMJType 1 diabetes mellitus - Symptoms, diagnosis and treatment | BMJ Best Practice US Identification of at-risk individuals through screening enables specialist assessment and discussion of treatment burden, adverse effects, and expected delay in clinical disease. BMJBMJType 1 diabetes mellitus - Symptoms, diagnosis and treatment | BMJ Best Practice US

Pancreas or islet transplantation can normalize glucose and mitigate microvascular complications but requires lifelong immunosuppression. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 Pancreas transplantation should generally be reserved for people undergoing kidney transplantation, after kidney transplant, or with recurrent DKA or severe hypoglycemia despite optimized management. ccjmccjm9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025

Donislecel-jujn (Lantidra) is the FDA-approved allogeneic deceased-donor islet cell therapy for adults with type 1 diabetes who cannot approach target A1C because of repeated severe hypoglycemia despite intensive diabetes management and education. fdafdaFDA Approves First Cellular Therapy to Treat Patients with Type 1 Diabetes | FDA It is infused into the hepatic portal vein; additional infusion may be considered based on response. fdafdaFDA Approves First Cellular Therapy to Treat Patients with Type 1 Diabetes | FDA In two nonrandomized single-arm studies of 30 participants, 21 achieved insulin independence for at least 1 year, including 10 for more than 5 years; five achieved no insulin-independent days. fdafdaFDA Approves First Cellular Therapy to Treat Patients with Type 1 Diabetes | FDA Procedure and immunosuppression-related serious adverse reactions were common and can lead to loss of graft function if immunosuppression must be discontinued. fdafdaFDA Approves First Cellular Therapy to Treat Patients with Type 1 Diabetes | FDA